Bangladesh, as a member state of the World Health Organization-South East Asia Regional Office (WHO-SEARO) and the United Nations, has responded to the call to address antimicrobial resistance (AMR) by preparing a National Strategy and Action Plan for AMR. Bangladesh has taken the initiative to implement integrated activities, including a national antibiotic surveillance system and laboratory network, and collaborating with the member countries of WHO-SEARO and other countries globally. Bangladesh is a member of the “Global Antibiotic Resistance Partnership (GARP)” project, which is technically supported by the Center for Disease Dynamics, Economics & Policy (CDDEP). It is committed to assisting with the “National Strategy and Action Plan on AMR” in preserving antibiotic effectiveness, slowing down the spread of AMR, and establishing national capacity for antibiotic policy and access.

The situation analysis of AMR has attempted to analyze the scope, extent, and magnitude of the development and spread of resistant microbes and reviewed the functions, roles, and responsibilities of the stakeholders. These include (i) the pharmaceutical industry as an entity for the manufacture of antimicrobial drugs; (ii) the intermediary groups as an entity of procuring and supplying antimicrobial drugs, such as directorates, institutions, organizations, groups, business parties and wholesale/retail pharmacies to the end users; (iii) the end user groups, such as clinicians, medical practitioners and veterinarians prescribing antimicrobials drugs for patients – both for human and animal population; and (iv) the Directorate General of Drug Administration (DGDA), as a National Regulatory Authority (NRA), implementing drug regulations at all stages of productions, including the dispenses of medicines in Bangladesh.

The full report is available for download (above).